Answers are grounded in this paper and cite their sources.
G12C-mutant NSCLC, including dual checkpoint blockade and combinations with checkpoint inhibitors, with a focus on the setting of advanced disease.
No takes yet. Share an insight, caveat, or question.
Ghazali et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: